As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to the potential of closed-loop insulin delivery systems.
Major medical technology companies, including Medtronic and Insulet, touted data at this year’s meeting demonstrating the benefits of their systems that connect glucose monitoring data and insulin dosing. Patient advocacy groups, like the JDRF, have called on the industry to fund and develop automated insulin delivery systems – echoing the calls of a community of people with diabetes that have already been doing this themselves.
Industry players seem to have taken the hint from the diabetes community. Here’s a look at what they’re working on.
NEXT: Medtronic touts real-world outcomes for MiniMed 670G